Cellular, Immune and Gene Therapy for Cancer



This theme involves the development and clinical trialling of novel therapies for cancer based on two principles

- using the specificity of the cellular immune system to recognise and kill tumour cells selectively
- using vector-mediated delivery to tumour cells of genes that sensitise the cells to chemotherapeutic pro-drugs.

For both approaches, viruses provide an important entrée. Thus virus-associated cancers are key targets of choice for the development of immune therapies, while other viruses provide the key vectors for tumour-specific gene delivery.

This work complements and extends that described in the **Viral Oncology (/research/activity/mds/domains/Cancer/viral-oncology/index.aspx)** Theme.

Open all sections

Gene therapy research

- **Nitroreductase for prodrug activation gene therapy (/research/activity/mds/domains/Cancer/cell-immune-gene-therapy/gene-therapy-research/index.aspx)** (**Dr P Searle (/staff/profiles/cancer/searle-peter.aspx)**)

Immunotherapy research

- Cellular and Immune therapy for leukaemia (**Prof P Moss (/staff/profiles/cancer/moss-paul.aspx)**)
- Harnessing the immune system to treat cancer (**Dr G Taylor (/staff/profiles/cancer/taylor-graham.aspx)**)
- **T cell-based therapies for cancer (/research/activity/mds/domains/Cancer/cell-immune-gene-therapy/t-cell-therapies/index.aspx)** (**Dr S Lee (/staff/profiles/cancer/lee-steven.aspx)**)